Literature DB >> 11776150

Human monocyte-derived dendritic cells expressing both chemotactic cytokines IL-8, MCP-1, RANTES and their receptors, and their selective migration to these chemokines.

K Zhu1, Q Shen, M Ulrich, M Zheng.   

Abstract

OBJECTIVE: To characterize the mRNA expression of CXC chemokine IL-8, CC chemokine monocyte chemothractant protein-1 (MCP-1) and regulated on activation, normal T cell expressed and secreted (RANTES), and a newly defined DC chemokine DC-CK1 as well as the expression of IL-8 receptor, MCP-1 receptor and RANTES receptor in human monocyte-derived dendritic cells (MoDCs). The migratory responsiveness of MoDC to IL-8, MCP-1 and RANTES was also studied.
METHODS: In vitro generated MoDCs were obtained by differentiating monocytes in the presence of GM-CSF and IL-4 for 5 days. The time course of RNA expression was analyzed by RT-PCR and migratory ability was assessed by a micromultiwell chemotaxis chamber assay.
RESULTS: IL-8, MCP-1, RANTES and their corresponding receptors were consistently expressed in MoDCs. DC-CK-1 expression was detectable after 48 hours of differentiation. MoDC selectively migrated in response to MCP-1 and RANTES but not to IL-8 though transcripts of IL-8 receptor were present.
CONCLUSION: Because the capacity of dendritic cells to initiate immune responses depends on their specialized migratory and tissue homing properties, the expression of chemokines and their receptors along with the migratory responsiveness to chemokines of MoDC in our study suggests a potential role of chemokines in the interaction between dendritic cells and T cells and the induction of immune responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11776150

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  9 in total

1.  Inflammatory events in a vascular remodeling model induced by surgical injury to the rat carotid artery.

Authors:  Barbara Rinaldi; Paolo Romagnoli; Stefano Bacci; Rosa Carnuccio; Maria Chiara Maiuri; Maria Donniacuo; Annalisa Capuano; Francesco Rossi; Amelia Filippelli
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 2.  Recent Advances in Good Manufacturing Practice-Grade Generation of Dendritic Cells.

Authors:  Sarah Cunningham; Holger Hackstein
Journal:  Transfus Med Hemother       Date:  2020-10-28       Impact factor: 3.747

3.  Changes in serum immunomolecules during antibiotic therapy for Mycobacterium avium complex lung disease.

Authors:  S-Y Kim; W-J Koh; H Y Park; K Jeon; O J Kwon; S-N Cho; S J Shin
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

4.  CCL20 is overexpressed in Mycobacterium tuberculosis-infected monocytes and inhibits the production of reactive oxygen species (ROS).

Authors:  O M Rivero-Lezcano; C González-Cortés; D Reyes-Ruvalcaba; C Diez-Tascón
Journal:  Clin Exp Immunol       Date:  2010-09-01       Impact factor: 4.330

5.  Tissue sodium content in patients with systemic lupus erythematosus: association with disease activity and markers of inflammation.

Authors:  D A Carranza-León; A Oeser; A Marton; P Wang; J C Gore; J Titze; C M Stein; C P Chung; M J Ormseth
Journal:  Lupus       Date:  2020-02-18       Impact factor: 2.911

6.  Maturation of dendritic cells depends on proteolytic cleavage by cathepsin X.

Authors:  Natasa Obermajer; Urban Svajger; Mathew Bogyo; Matjaz Jeras; Janko Kos
Journal:  J Leukoc Biol       Date:  2008-08-13       Impact factor: 4.962

7.  CCL20/CCR6 blockade enhances immunity to RSV by impairing recruitment of DC.

Authors:  Lara E Kallal; Matthew A Schaller; Dennis M Lindell; Sergio A Lira; Nicholas W Lukacs
Journal:  Eur J Immunol       Date:  2010-04       Impact factor: 5.532

Review 8.  More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis.

Authors:  Martha Gschwandtner; Rupert Derler; Kim S Midwood
Journal:  Front Immunol       Date:  2019-12-13       Impact factor: 7.561

9.  Alocasia cucullata exhibits strong antitumor effect in vivo by activating antitumor immunity.

Authors:  Qiuxian Peng; Hongbing Cai; Xuegang Sun; Xin Li; Zhixian Mo; Jue Shi
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.